Home › Compare › NOXOF vs XYLD

NOXOF vs XYLD: Dividend Comparison 2026

NOXOF yields 4444.44% · XYLD yields 10.93%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NOXOF wins by $19857738408180.45M in total portfolio value
10 years
NOXOF
NOXOF
● Live price
4444.44%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19857738408180.48M
Annual income
$19,016,069,933,146,186,000.00
Full NOXOF calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.93%
Share price
$39.31
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.1K
Annual income
$3,189.45
Full XYLD calculator →

Portfolio growth — NOXOF vs XYLD

📍 NOXOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNOXOFXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NOXOF + XYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NOXOF pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NOXOF
Annual income on $10K today (after 15% tax)
$377,777.78/yr
After 10yr DRIP, annual income (after tax)
$16,163,659,443,174,257,000.00/yr
XYLD
Annual income on $10K today (after 15% tax)
$929.36/yr
After 10yr DRIP, annual income (after tax)
$2,711.03/yr
At 15% tax rate, NOXOF beats the other by $16,163,659,443,174,255,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NOXOF + XYLD for your $10,000?

NOXOF: 50%XYLD: 50%
100% XYLD50/50100% NOXOF
Portfolio after 10yr
$9928869204090.25M
Annual income
$9,508,034,966,573,095,000.00/yr
Blended yield
95.76%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NOXOF buys
0
XYLD buys
0
No recent congressional trades found for NOXOF or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNOXOFXYLD
Forward yield4444.44% ✓10.93%
Annual dividend / share$2.00$4.30 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$19857738408180.48M ✓$25.1K
Annual income after 10y$19,016,069,933,146,186,000.00 ✓$3,189.45
Total dividends collected$19800558376185.16M ✓$19.4K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: NOXOF vs XYLD ($10,000, DRIP)

YearNOXOF PortfolioNOXOF Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$455,144$444,444.44$10,813$1,093.36+$444.3K → NOXOF
2$19,392,277$18,905,272.87$11,727$1,216.35+$19.38M → NOXOF
3$773,548,232$752,798,494.96$12,756$1,357.11+$773.54M → NOXOF
4$28,891,953,466$28,064,256,857.57$13,917$1,518.69+$28891.94M → NOXOF
5$1,010,538,077,568$979,623,687,360.21$15,232$1,704.71+$1010538.06M → NOXOF
6$33,103,483,882,921$32,022,208,139,922.89$16,725$1,919.54+$33103483.87M → NOXOF
7$1,015,787,352,937,823$980,366,625,183,097.90$18,425$2,168.40+$1015787352.92M → NOXOF
8$29,201,617,438,828,424$28,114,724,971,184,950.00$20,367$2,457.63+$29201617438.81M → NOXOF
9$786,606,051,433,916,900$755,360,320,774,370,600.00$22,592$2,794.87+$786606051433.89M → NOXOF
10$19,857,738,408,180,478,000$19,016,069,933,146,186,000.00$25,149$3,189.45+$19857738408180.45M → NOXOF

NOXOF vs XYLD: Complete Analysis 2026

NOXOF — Stock

Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.

Full NOXOF Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this NOXOF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NOXOF vs SCHDNOXOF vs JEPINOXOF vs ONOXOF vs KONOXOF vs MAINNOXOF vs QYLDNOXOF vs JEPQNOXOF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.